CALENDAR
S M T W T F S
     12
3456789
10111213141516
17181920212223
24252627282930
31      
<< March 2024 >>
ARCHIVES
CATEGORIES
MOBILE
qrcode
<< ¥µ¥Î¥Õ¥£¤Î¥¤¥ó¥¹¥ê¥ó¥¢¥Ê¥í¥°À½ºÞ¥é¥ó¥¿¥¹¤È¥®¥ê¥¢¥É¼Ò¤ÎC·¿´Î±ê¼£ÎÅÌô¥Ï¡¼¥Ü¥Ë¡¼¤¬ÆüËܤǾµÇ§ | main | FDA»ðÌä°Ñ°÷²ñ¤Ï9Æü¡ÊÌڡˤËnecitumumab¤ò¿³µÄ¡ÝFDA¤Ï·ìÀò¥ê¥¹¥¯Áý²Ã¤ò·üÇ° >>
¥Î¥Ð¥ë¥Æ¥£¥¹¤Î¿·µ¬¿´ÉÔÁ´¼£ÎÅÌôEntresto¡ÊLCZ696¡Ë¤¬FDA¤Ë¾µÇ§¤µ¤ì¤¿
0
    PharmaTimes¤Îµ­»ö¡ÖNovartis' heart failure drug gets speedy US approval¡×¤«¤é¤Ç¤¹¡£

    ¥Î¥Ð¥ë¥Æ¥£¥¹¤Î¿´ÉÔÁ´¼£ÎÅÌôEntresto¡ÊLCZ696¡Ë¤¬¿³ºº´ü¸Â¤è¤ê¤â6½µ´ÖÁ᤯FDA¤Ë¾µÇ§¤µ¤ì¤Þ¤·¤¿¡£¼£ÎÅÂоݤȤʤ봵¼Ô¤Ï¡¢µ­»ö¤Îµ­ºÜ¤ò¤½¤Î¤Þ¤Þ²¼¤Ë¥³¥Ô¡¼¤·¤Æ¤ª¤­¤Þ¤¹¡£
    heart failure with reduced ejection fraction in patients whose condition is classified NYHA class II-IV, indicated to cut the risk of cardiovascular death and heart failure hospitalisation.

    Entrest¤Ï¡¢¿·µ¬¥¯¥é¥¹¤Î¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¼õÍÆÂΡݥͥץê¥é¥¤¥·¥óÁ˳²Ìô¤Ç¤¢¤ê¡¢¥Í¥×¥ê¥é¥¤¥·¥ó¡ÊARNI¡ËÁ˳²Ìôsacubitril¤È¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¼õÍÆÂÎÙɹ³Ìô¡ÊARB¡Ë¥Ð¥ë¥µ¥ë¥¿¥ó¤Î¹çºÞ¤Ç¤¹¡£¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó­¶¼õÍÆÂΤÎÁ˳²¤È¤È¤â¤Ë¡¢Æâ°øÀ­¥Ê¥È¥ê¥¦¥àÍøÇ¢¥Ú¥×¥Á¥É¤Îʬ²ò¤Ë¤«¤«¤ï¤ë¥Í¥×¥ê¥é¥¤¥·¥óÁ˳²¤Ë¤è¤ëÆâ°øÀ­¥Ê¥È¥ê¥¦¥àÍøÇ¢¥Ú¥×¥Á¥É¤Îʬ²òÍÞÀ©ºîÍѤò¼¨¤¹¤³¤È¤Ë¤è¤ê¿´ÉÔÁ´²þÁ±¸ú²Ì¤¬ÆÀ¤é¤ì¤ë¤È¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

    µ­»ö¤Ï¡¢Entresto¤¬¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óÊÑ´¹¹ÚÁÇÁ˳²Ìô¡ÊACEÁ˳²Ìô¡Ë¤Î¥¨¥Ê¥é¥×¥ê¥ë¤ÈÈæ¤Ù¤Æ¿´·ì´É»à¤òÌó20%¸º¾¯¤·¤¿¤³¤È¤ò½Ò¤Ù¤Æ¤¤¤Þ¤¹¡£¤³¤Î»î¸³¡ÊPARADIGM»î¸³¡Ë¤Ï¡¢Ãæ´Ö²òÀϤÇÂоÈÌô¤è¤ê¤âÎɹ¥¤ÊÍ­¸úÀ­¤¬³Îǧ¤µ¤ì¤¿¤³¤È¤«¤éÁá´ü½ªÎ»¤µ¤ì¤Æ¤¤¤Þ¤·¤¿¡£»î¸³·ë²Ì¤Ï¡¢NEJM»ï¤Ëȯɽ¤µ¤ì¤Æ¤¤¤Þ¤¹¡Ê²¼µ­¥ê¥ó¥¯Àè¡Ë¡£
    Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    ¼ç¤ÊÉûºîÍѤȤ·¤Æ¡¢Äã·ì°µ¡¢¹â¥«¥ê¥¦¥à·ì¾É¡¢¿ÕÉÔÁ´¤ÎÊó¹ð¤¬¤¢¤ê¤Þ¤¹¡£¤Þ¤¿¡¢¥Î¥Ð¥ë¥Æ¥£¥¹¤ÏÈÝÄꤷ¤Æ¤¤¤Þ¤¹¤¬¡¢Ç§Ãξɥꥹ¥¯¤òÁý²Ã¤µ¤»¤ë¤È¤ÎÊó¹ð¤â¤¢¤ê¤Þ¤·¤¿¡£
    New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer's Disease?

    À¸Â¸Î¨¤¬Áý²Ã¤¹¤ë¤³¤È¤«¤é¡¢°å»Õ¤ÏACEÁ˳²Ìô¤ËÂå¤ï¤Ã¤ÆEntresto¤ò½èÊý¤¹¤ë¤Ç¤·¤ç¤¦¡£

    LCZ696¤Ë¤Ä¤¤¤Æ¤Ï¡¢Åö¥Ö¥í¥°¤Ç²áµî¤Ë¼è¤ê¾å¤²¤Æ¤¤¤Þ¤·¤¿¡£
    ¥Î¥Ð¥ë¥Æ¥£¥¹¤Ï³«È¯Ãæ¤Î¿´ÉÔÁ´¼£ÎÅÌôLCZ696¤ËÂ礭¤Ê´üÂÔ
    | ¤½¤Î¾¥×¥é¥¤¥Þ¥ê¡¼Îΰè | 08:13 | comments(0) | - |